| __timestamp | Intra-Cellular Therapies, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 11606000000 |
| Thursday, January 1, 2015 | 18187286 | 10313000000 |
| Friday, January 1, 2016 | 24758063 | 9762000000 |
| Sunday, January 1, 2017 | 23666957 | 9830000000 |
| Monday, January 1, 2018 | 30099855 | 10102000000 |
| Tuesday, January 1, 2019 | 64947625 | 10615000000 |
| Wednesday, January 1, 2020 | 186363444 | 8955000000 |
| Friday, January 1, 2021 | 272611040 | 9634000000 |
| Saturday, January 1, 2022 | 358782000 | 10042000000 |
| Sunday, January 1, 2023 | 409864000 | 10504000000 |
Unlocking the unknown
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Merck & Co., Inc. and Intra-Cellular Therapies, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Merck's SG&A expenses have shown a slight decline, dropping by approximately 10% from their peak in 2014. This indicates a strategic focus on cost efficiency, despite their large scale. In contrast, Intra-Cellular Therapies has seen a significant increase in SG&A expenses, rising nearly 40 times over the same period. This surge reflects their aggressive growth strategy and investment in market expansion. While Merck's approach highlights stability and efficiency, Intra-Cellular's strategy underscores the challenges and opportunities of scaling up. Understanding these trends offers valuable insights into the financial strategies of leading pharmaceutical companies.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Merck & Co., Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Novartis AG
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Evotec SE Trends and Insights
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights